Human Papillomavirus Vaccine Market Report

Market Insights

The Human Papillomavirus Vaccine Market is estimated to grow from USD 3.2 billion in 2020 to USD 4.6 billion by 2026 at a healthy CAGR of 6.7% during the forecast period.

Figure: Human Papillomavirus Vaccine Market Size, 2020-2026 (USD Billion)

Wish to get a free sample? Register Here

What is Human Papillomavirus Vaccine?

Human papillomaviruses causes numerous types of cancers such as anal cancer, cervical cancer, penile cancer, vaginal cancer, oropharyngeal cancer, vulvar cancer, and genital warts. The human papillomavirus infection is prevented by the vaccination against human papillomavirus. Human papillomaviruses is a wide group of DNA-based viruses which is likely to infect the mucous and skin membranes of humans and various animals.

Covid-19 Impact Analysis

The ongoing COVID-19 pandemic has had a devastating impact on the HPV associated disorders industry. The healthcare industry is currently facing major challenges as it is unable to provide proper medical facilities to meet the ever-growing coronavirus patient pool. With the stringent imposition of lockdown and social distance regulations, there were limited check-ups of women suffering from sexually transmitted diseases. During the pandemic period in 2020, around 342,000 women lost their lives due to cervical cancer. Thus, poor healthcare system due to limited medical professionals and funding affected the market growth.

Key Players

Key players operating in the global Human Papillomavirus Vaccine Market are-

• Merck & Co., Inc. (US)
• GlaxoSmithKline Plc (UK)
• Sanofi S.A. (France)
• Johnson & Johnson (US)
• AstraZeneca Plc (UK)
• Serum Institute of India Pvt. Ltd. (India)
• Bharat Biotech (India)
• Bavarian Nordic (Denmark)
• Inovio Pharmaceuticals (US)

Market Dynamics

The Human Papillomavirus Vaccine market is majorly propelled by increasing prevalence of various cancers caused by human papillomavirus. Also, growing initiatives by government & private organizations for early screening & vaccination and approval of new HPV vaccines. The growing incidence of HPV associated cancers such as oropharynx, anal, and genital parts as well as surging demand for HPV vaccines to reduce infections further boosts the market growth in the coming years.

Segment’s Analysis

Indication Trends

Based on indication, the human papillomavirus vaccine market has been classified into cervical cancer, anal cancer, penile cancer, oropharyngeal cancer, genital warts, and others. The cervical cancer segment accounted for the largest market in 2020. Almost all types of cervical cancer are caused by human papillomavirus (HPV). Also, there are highly sensitive and specific molecular tests now available to identify from DNA, the high-risk HPV types, in cervical cancer screening, which bolsters the segment growth.

Regional Trends

By region, the North America Human Papillomavirus Vaccine market accounted the highest share in 2020 and is expected to grow at a robust CAGR during the review period. The Human Papillomavirus Vaccine market growth is mainly attributed to surge in healthcare expenditure, robust commercial sales of biologics in the U.S., technologically advanced healthcare infrastructure, and well-established healthcare companies. Moreover, growing healthcare expenditure and proactive government initiatives,, further boosts the regional growth, thus augmenting the market growth.

The Asia Pacific Human Papillomavirus Vaccine market is expected to grow at the healthy CAGR during the review period due to increasing healthcare expenditure in emerging countries and rising STDs, and increasing awareness regarding vaccines for HPV in emerging countries of China and India, further bolsters the regional market growth.

Critical Questions Answered in the Report

This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global human papillomavirus vaccine market. The historic years considered for the study are 2016-2019, base year is 2020, estimated year is 2021, and forecast period is 2022-2026. Following are the critical questions answered in the report.

• What are the key trends in the global human papillomavirus vaccine market?
• How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in next five years?
• What is the impact of COVID-19 on global human papillomavirus vaccine market?
• What are the key strategies adopted by the major vendors to lead in the global human papillomavirus vaccine market?
• What is the market share of the top vendors?

Target Audience

The target audience of Human Papillomavirus Vaccine Market includes-

• Human Papillomavirus Vaccine Vendors
• Human Papillomavirus Vaccine Manufacturers
• Human Papillomavirus Vaccine Distributors
• Organizations
• Government Bodies.

Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.